Pharmaengine, Inc. · TPEX:4162
Pharmaengine — 1H 2026 Investors' Conference
20 slides from Pharmaengine's conference presentation, Aug 6, 2026
Slide 1: PharmaEngine 1H 2026 Investors' Conference
PharmaEngine, Inc. 4162.TWO 1H 2026 Investors’ Conference 2026/08/06 Roger Hsieh, Associate Director, Business Development Jackie Chang, Senior Manager, Investor Relations
Slide 2: Disclaimer
Disclaimer This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes,’ ‘expects,’ ‘anticipates,’ ‘projects,’ ‘intends,’ ‘should,’ ‘seeks,’ ‘estimates,’ ‘future,’ or similar expressions or by discussion of, among other
Slide 3: Agenda
AGENDA 1. 1H 2026 Operational Highlights 2. 1H 2026 Operational Overview 3. R&D Pipeline and Related Markets Update ◆ PEP07 (CHK1 Inhibitor) ◆ PEP08 (2nd Generation PRMT5 Inhibitor) 4. Company Outlook 5. Q&A
Slide 4: 1H 2026 Operational Highlights: Sustainable Growth and Enhanced Pipeline
1H 2026 Operational Highlights: Sustainable Growth and Enhanced Pipeline COMMERCIAL PIPELINE OPERATION ONIVYDE® Expand R&D Pipeline Operation with Indication Expansion Acceleration Sustainable Growth 1. Sales of 1L combination 1. PEP07 Phase I clinical trials 1. 1H26 cash and cash therapy of ONIVYDE
Slide 5: 1H 2026 Operational Overview
1H 2026 OPERATIONAL OVERIVEW
Slide 6: Sales and Royalties Drive Long-term Growth
Sales and Royalties Drive Long-term Growth NT$(000) 1H 2026 Item Year 2019 2020 2021 2022 2023 2024 2025 YoY (%) Taiwan Sales 180,389 214,828 235,469 277,594 278,547 279,990 277,133 131,457 (+3%) Royalties from 133,651 271,584 419,366 376,789 426,652 543,286 627,762 312,684 (+25%) Europe and Asia Mi
Slide 7: 1H 2026 Financial Results
1H 2026 Financial Results NT$(000) 1H 2026 1H 2025 Amount Change % Change Operating revenue 497,811 384,169 113,646 30% Operating costs 34,186 23,207 10,979 47% Gross profit 463,625 360,962 102,663 28% Sales expenses 16,615 15,091 1,524 10% G&A expenses 48,395 45,781 2,614 6% R&D expenses 152,271 11
Slide 8: R&D Pipeline and Related Markets Update
R&D Pipeline and Related Markets Update
Slide 9: Pipeline Portfolio Focuses on Precision Oncology
Pipeline Portfolio Focuses on Precision Oncology Commercial Program Indications Lead Preclinical Phase I Phase II Phase III Approval Partner Rights Milestone Royalty ONIVYDE® (EU/Asia) 1L/2L PDAC Approval (liposomal irinotecan) Taiwan Sales AML/MCL PEP07 Global (CHK1i) Solid tumors DDR & PEP08 MTAP-
Slide 10: PEP07: CHK1 Inhibitor
PEP07: CHK1 Inhibitor Highly potential indications and number of patients (2022 GLOBOCAN data) Mechanism ✓ Acute Myeloid Leukemia (2022: 165,500 incidences) PEP07 is a checkpoint kinase 1 (CHK1) ✓ Mantle Cell Lymphoma (2022: 33,323 incidences) inhibitor which targets the DNA Damage Response (DDR) pa
Slide 11: PEP07: Phase I Clinical Trial Update
PEP07: Phase I Clinical Trial Update Target Population Phase I Monotherapy for patients with advanced or Hema metastatic hematologic cancers and solid Selected indications and tumor ; combo studies for the selected combination studies cancer types. Phase I Solid Dose Escalation Endpoint • Maximum To
Slide 12: PEP08: Second-Generation PRMT5 Inhibitor
PEP08: Second-Generation PRMT5 Inhibitor Highly potential indications (MTAP-deletion) and number of patients (2022 GLOBOCAN data) Mechanism ✓ Glioblastoma (2022: 135,020 incidences) PEP08 is a second-generation MTA- ✓ Lung Cancer (2022: 274,040 incidences) cooperative, PRMT5 inhibitor and a highly ✓
Slide 13: PEP08: Phase I Clinical Trial Update
PEP08: Phase I Clinical Trial Update Cohort 5 Target Population Cohort 4 Patients with advanced or metastatic MTAP- deficient solid tumors Cohort 3 Dose Escalation Endpoint Cohort 2 • Maximum Tolerated Dose (MTD) and Cohort 1 Recommended Phase 2 Dose (RP2D) • Pharmacokinetics (PK), Pharmacodynamics
Slide 14: Combination Therapy: A Major Trend in Modern Cancer Treatment
Combination Therapy: A Major Trend in Modern Cancer Treatment Combination Therapy Combination therapy has emerged as a key approach in cancer treatment. By integrating therapies with different mechanisms of action, it can enhance treatment efficacy, extend disease control, and reduce the risk of dru
Slide 15: PEP07 + PEP08 Combo Therapy Shows Therapeutic Potential in CDX Model
PEP07 + PEP08 Combo Therapy Shows Therapeutic Potential in CDX Model Pancreatic Cancer CDX GBM (brain cancer) CDX Vehicle Control Vehicle Control PEP07 PEP07 PEP08 PEP08 PEP07 + PEP08 PEP07 + PEP08 PEP07 + PEP08 combination therapy shows synergistic effects in pancreatic cancer and GBM (brain cancer
Slide 16: Company Outlook
L Company Outlook
Slide 17: Business Development Momentum
Business Development Momentum Clinical Trial Collaboration • Actively explore the potential preclinical and clinical partners for PEP07 and PEP08 • Target on selected indications • On-market drugs or under-developed drugs • International and domestic academic research institutions, medical centers,
Slide 18: Innovative Drug Development & AI Platform Strategic Collaboration
Innovative Drug Development & AI Platform Strategic Collaboration Innovative Drug Development Strategy PharmaEngine aims to drive innovative drug discovery and to strengthen in-house CADD to Generative AI R&D capabilities. Since 2022, we partnered with leading AI drug discovery companies. Before 202
Slide 19: Company Outlook (2H26 Onward)
Company Outlook (2H26 Onward) 1 Begin the combination study for PEP07 4 Actively looking for out-licensing and clinical collaboration partners 2 Complete dose escalation for PEP08 5 Collaborate with AI Drug Discovery partner to expand PEI portfolio 3 Accelerate the R&D pipeline combination 6 30% of
Slide 20: Thank You
THANK YOU PharmaEngine, Inc.